Lurbinectedin - PharmaMar

Drug Profile

Lurbinectedin - PharmaMar

Alternative Names: PM-01183; PM-1183; Tryptamicidin; Zepsyre

Latest Information Update: 14 Oct 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator PharmaMar
  • Developer Fundacion Instituto Valenciano de Oncologia; PharmaMar; Swiss Group for Clinical Cancer Research
  • Class 3-ring heterocyclic compounds; Acetates; Alkaloids; Antineoplastics; Dioxolanes; Indoles; Small molecules; Tetrahydroisoquinolines
  • Mechanism of Action Alkylating agents; Cell cycle inhibitors; RNA polymerase II inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Ovarian cancer
  • New Molecular Entity Yes

Highest Development Phases

  • Phase III Ovarian cancer; Small cell lung cancer
  • Phase II Breast cancer; Mesothelioma; Non-small cell lung cancer; Pancreatic cancer; Sarcoma; Solid tumours
  • Phase I Leukaemia

Most Recent Events

  • 10 Oct 2017 Interim efficacy data from a phase I trial in Solid tumours released by PharmaMar
  • 28 Sep 2017 Phase-II clinical trials in Mesothelioma (Monotherapy, Second-line therapy or greater) in Switzerland (IV) (NCT03213301)
  • 12 Sep 2017 Efficacy data from a phase II trial in Small-cell lung cancer presented at the 42nd European Society for Medical Oncology Congress (ESMO-2017)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top